Neutrophil Count

Introduction

Neutrophils are the most abundant type of white blood cell (leukocyte) and serve as a crucial component of the innate immune system, acting as the body’s first line of defense against infection and inflammation.^[1]Their primary role involves phagocytosis, where they engulf and destroy invading microorganisms and cellular debris. A neutrophil count refers to the number of these cells present in a microliter of blood, typically measured as part of a complete blood count (CBC). This count is a vital indicator of an individual’s immune status and overall health, with deviations from the normal range often signaling underlying medical conditions.

Biological Basis

Neutrophils are produced in the bone marrow and released into the bloodstream, where they have a relatively short lifespan. The regulation of neutrophil production and migration is complex, involving various hematopoietic cytokines.^[2]The neutrophil count is a moderately heritable trait, with genetic factors explaining a significant portion of its variation.^[1]Genome-wide association studies (GWAS) have identified several genetic loci associated with neutrophil count. For example, a regulatory variant in theDARC(Duffy Antigen Receptor for Chemokines) gene is known to influence neutrophil levels, particularly contributing to lower counts observed in people of African descent.^[3]This variant can alter the concentration and distribution of chemokines, thereby impacting neutrophil production and migration.^[3] Other important loci include the PSMD3-CSF3region on chromosome 17q21, where variations are associated with neutrophil count andPSMD3 expression.^[4] The CDK6 gene on chromosome 7, which regulates cell cycle progression and inhibits granulocytic differentiation, also contains variants like rs445 linked to neutrophil levels.^[3]

Clinical Relevance

Abnormal neutrophil counts can have significant clinical implications. A lower-than-normal neutrophil count, known as neutropenia, can increase susceptibility to infections, as the body’s ability to fight off pathogens is compromised. Severe congenital neutropenia, for instance, is inherited as a rare, monogenic disorder.^[5]Conversely, an elevated neutrophil count (neutrophilia) can indicate an ongoing infection, inflammation, or other stress on the body. Understanding an individual’s neutrophil count is crucial in diagnosing and managing various conditions, including inflammatory diseases, certain cancers, and in guiding treatments such as chemotherapy, which can induce neutropenia.^[3]Total white blood cell count, which is largely driven by neutrophil count, has also been associated with cardiovascular disease risk factors such as high blood pressure, smoking, adiposity, and inflammatory markers.^[1]

Social Importance

Genetic variations in neutrophil count have notable social importance, particularly in understanding population-specific differences. A phenomenon known as benign ethnic neutropenia (BEN) describes lower neutrophil counts that are common in individuals of African descent but are not typically associated with increased risk of infection.^[6] This genetic predisposition, largely attributed to the DARCgene variant, highlights the importance of establishing population-specific normal ranges for neutrophil counts to avoid misdiagnosis or unnecessary interventions.^[6]Recognizing these ethnic differences is critical for equitable healthcare, ensuring that clinical decisions are informed by genetic background and do not lead to health disparities. Studies across diverse populations, including African Americans, Europeans, and Japanese individuals, continue to uncover the complex genetic architecture underlying neutrophil count, contributing to a more nuanced understanding of human health.^[3]

Restricted Population Generalizability and Ancestry Bias

A primary limitation in understanding the genetic architecture of neutrophil count stems from the predominant focus on populations of European ancestry in many genome-wide association studies (GWAS). Imputation reference panels, such as HapMap Phase 2 European CEU founders, and study cohorts, including the UK Biobank’s self-reported European individuals and various replication samples from European countries, largely confine the observed genetic associations to these specific groups.^[7]This reliance on a narrow demographic restricts the generalizability of findings, as allele frequencies, linkage disequilibrium patterns, and genetic effects can vary significantly across different ancestral backgrounds. Consequently, genetic variants influencing neutrophil count in non-European populations may remain undiscovered or poorly characterized, limiting the clinical utility and biological insights for a diverse global population.

Furthermore, population stratification, even within broad European cohorts, presents a challenge, as exemplified by the use of AIM SNPs to differentiate Northern versus Southern European ancestry, which can lead to an overestimation of inflation in association signals.^[8] While methods like EIGENSTRAT are employed to correct for such stratification, residual biases can persist, potentially obscuring true associations or generating spurious ones.^[8]The lack of extensive genetic data from diverse populations means that the identified genetic loci for neutrophil count may not be universally applicable, necessitating further research in underrepresented groups to achieve a comprehensive understanding of its genetic determinants.

Methodological and Statistical Constraints

The analytical approaches employed in GWAS for traits like neutrophil count, while powerful, introduce several methodological and statistical limitations. The filtering of genetic variants based on minor allele frequency (MAF > 0.1% or > 1%) and imputation quality scores (INFO > 0.8) means that rare variants, which may have substantial effects on neutrophil count, are often excluded or less reliably detected.^[7] This selective analysis contributes to the “missing heritability” phenomenon, where a significant portion of the heritable variation for a trait remains unexplained by common variants identified through GWAS. Additionally, while large sample sizes are crucial for detecting small genetic effects, some simulations or initial discovery phases might use smaller subsets, potentially impacting statistical power for certain associations.^[9] Despite rigorous statistical corrections, such as genomic control and meta-analysis adjustments for heterogeneity using Cochran’s Q test, residual inflation of test statistics can still occur, particularly if the correction methods are overly conservative or if underlying population structures are complex.^[7] The failure to replicate all initial strong GWAS signals, where some top associations do not reach significance in independent replication cohorts, highlights the potential for false positives or context-specific genetic effects.^[10]This underscores the need for robust replication studies across multiple independent cohorts to confirm associations and provides a more accurate estimation of effect sizes for genetic variants influencing neutrophil count.

Incomplete Genetic Architecture and Environmental Influences

The current understanding of genetic contributions to neutrophil count is likely incomplete, as GWAS primarily identifies common variants with small effect sizes, leaving a substantial portion of heritability unexplained. The focus on single nucleotide polymorphisms (SNPs) may also overlook other forms of genetic variation, such as structural variants or epigenetics, which could play a significant role in regulating neutrophil levels. Furthermore, while genetic factors are important, neutrophil count is a complex trait influenced by a myriad of environmental factors, including infections, inflammation, medications, lifestyle, and underlying health conditions, which are often not fully captured or accounted for in genetic studies.

The interplay between genetic predispositions and environmental exposures, known as gene-environment interactions, represents a crucial yet largely unexplored area that could significantly modulate neutrophil count. Without comprehensively addressing these interactions, the predictive power of genetic models for neutrophil count remains limited. Future research is needed to integrate detailed environmental data with genetic information, potentially using advanced models to unravel the complex etiology of neutrophil count variation and to identify the full spectrum of genetic and environmental determinants.

Variants

Genetic variations in several genes play a significant role in modulating neutrophil counts, a critical component of the innate immune system. Variants within or near genes likeACKR1, CDK6, and CSF3are particularly relevant due to their direct involvement in neutrophil biology. For instance,ACKR1(Atypical Chemokine Receptor 1), also known as Duffy antigen, acts as a scavenger receptor for various chemokines, regulating their availability for other receptors and influencing neutrophil trafficking and extravasation into tissues. Polymorphisms inACKR1, such as rs2814778 , rs12075 , and rs7550207 , can alter chemokine binding efficiency or receptor expression, thereby affecting the pool of circulating neutrophils and their ability to respond to inflammatory signals.^[11] Similarly, CDK6(Cyclin Dependent Kinase 6) is a key regulator of cell cycle progression, crucial for the proliferation of hematopoietic stem and progenitor cells in the bone marrow. The variantrs445 in CDK6could influence the rate of neutrophil production, with specific alleles potentially leading to higher or lower baseline neutrophil counts.^[11] The CSF3 gene (Colony Stimulating Factor 3), which encodes Granulocyte-Colony Stimulating Factor (G-CSF), is a primary regulator of granulopoiesis. Variants like rs12600856 , rs7221894 , and rs4794822 , located near or within CSF3 (and also spanning PSMD3), can directly impact G-CSF production or signaling, profoundly affecting the differentiation, maturation, and release of neutrophils from the bone marrow.

Other genes implicated in neutrophil count regulation includeCXCL2, GSDMA, and PSMD3, which are involved in immune response and cellular integrity. CXCL2(C-X-C Motif Chemokine Ligand 2) is a potent chemokine that acts as a chemoattractant, guiding neutrophils to sites of infection and inflammation. Variants such asrs1371794 , rs11725704 , and rs11733208 within the region encompassing CXCL2 (and PPBPP2) may alter its expression levels or functional activity, thereby modulating the efficiency of neutrophil recruitment and overall inflammatory responses.^[11] The GSDMA gene (Gasdermin A) is part of a family of proteins that mediate pyroptosis, an inflammatory form of programmed cell death crucial for host defense. Variants like rs9898547 and rs3859189 , located in the GSDMA-PSMD3intergenic region, could influence the susceptibility to pyroptosis, potentially affecting the release of pro-inflammatory signals that recruit neutrophils and thus impact neutrophil demand and counts.^[11] PSMD3 (Proteasome 26S Subunit, Non-ATPase 3), along with its associated variants rs11655264 , rs8070444 , and rs576566496 , encodes a component of the 26S proteasome, a cellular machinery vital for protein degradation. Proper proteasome function is essential for regulating immune signaling pathways and processing antigens, both of which can indirectly affect neutrophil development and function.

Further genetic variations contribute to the complex regulation of neutrophil levels through their roles in fundamental cellular processes and signaling pathways. TheSPTA1 gene (Spectrin Alpha, Non-Erythrocytic 1), with variant rs863326 , encodes a component of the spectrin cytoskeleton, which is crucial for maintaining cell shape, integrity, and motility. In neutrophils, an intact cytoskeleton is vital for migration, phagocytosis, and degranulation, meaning that variations in SPTA1 could influence their functional capacity and lifespan.^[11] CREB5 (cAMP Responsive Element Binding Protein 5), a transcription factor, is involved in regulating gene expression in response to diverse cellular signals. Variants such as rs56388170 , rs73684276 , and rs886816 in CREB5may alter the expression of genes involved in hematopoiesis or immune cell function, thereby indirectly affecting neutrophil production or survival.^[11] Other genes like CLK2 (CDC-Like Kinase 2, rs11577338 ), NTRK1 (Neurotrophic Receptor Tyrosine Kinase 1, rs2768762 ), PEAR1 (Platelet Endothelial Aggregation Receptor 1, also rs2768762 ), and CADM3-AS1(CADM3 Antisense RNA 1) highlight the broad genetic landscape influencing neutrophil counts. These genes are involved in processes ranging from RNA splicing (CLK2) and neurotrophic signaling (NTRK1) to platelet function (PEAR1) and gene regulation (CADM3-AS1), demonstrating that neutrophil count is a polygenic trait influenced by a wide array of cellular and systemic pathways.

Key Variants

RS ID	Gene	Related Traits
rs2814778 rs12075 rs7550207	ACKR1, CADM3-AS1	neutrophil count granulocyte count leukocyte quantity monocyte count myeloid leukocyte count
rs863326	SPTA1	monocyte count neutrophil count leukocyte quantity
rs9898547 rs3859189	GSDMA - PSMD3	level of phosphatidylcholine osteoclast-associated immunoglobulin-like receptor level of bone marrow proteoglycan in blood hepatocyte growth factor amount monocyte count
rs11577338	CLK2	monocyte count leukocyte quantity type 2 diabetes mellitus neutrophil count eotaxin
rs2768762	NTRK1 - PEAR1	leukocyte quantity neutrophil count platelet endothelial aggregation receptor 1 eosinophil count
rs1371794 rs11725704 rs11733208	PPBPP2 - CXCL2	neutrophil count myeloid leukocyte count
rs56388170 rs73684276 rs886816	CREB5	granulocyte percentage of myeloid white cells monocyte percentage of leukocytes leukocyte quantity neutrophil count granulocyte count
rs11655264 rs8070444 rs576566496	PSMD3	cysteine-rich secretory protein 3 level of carcinoembryonic antigen-related cell adhesion molecule 6 in blood level of C-type lectin domain family 4 member A in blood L-Selectin neutrophil count
rs12600856 rs7221894 rs4794822	PSMD3 - CSF3	leukocyte quantity neutrophil count granulocyte count myeloid leukocyte count
rs445	CDK6	leukocyte quantity eosinophil count neutrophil count granulocyte count basophil count

Genetic Predisposition and Heritability

Neutrophil count is significantly influenced by inherited genetic factors, with studies indicating moderate heritability estimates ranging from approximately 0.14 to 0.4 across total leukocyte counts and their subtypes.^{[12], [13]} In some cases, severe congenital neutropenia arises from rare, highly penetrant genetic variants, manifesting as monogenic disorders.^[5]Beyond these rare forms, common genetic polymorphisms distributed throughout the genome contribute to the natural variation in neutrophil counts observed within the general population.

Genome-wide association studies (GWAS) have pinpointed several key genetic loci. A notable example is a regulatory variant in the Duffy Antigen Receptor for Chemokines (DARC) gene, which is a major contributor to the reduced neutrophil count prevalent in individuals of African descent, accounting for roughly 20% of the total variation.^{[14], [15]} This variant leads to the absence of DARCexpression on red blood cells, which can alter chemokine concentrations and distribution in the blood and tissues, thereby impacting neutrophil production and migration.^[3] Other identified genetic regions include the PSMD3-CSF3 locus, where common variations like rs4794822 are associated with neutrophil count, with evidence suggesting an effect onPSMD3 expression, a component of the 26S proteasome involved in cell cycle regulation.^{[3], [16]} The PLCB4 locus and the CDK6 gene on chromosome 7, with variants such as rs445 , have also been linked to neutrophil count, withCDK6 being known for its role in cell cycle regulation and inhibition of terminal granulocytic differentiation.^{[3], [4]}

Environmental and Lifestyle Influences

Environmental and lifestyle factors are significant modulators of neutrophil count, contributing to observed population differences. Lifestyle choices such as cigarette smoking are associated with higher total white blood cell counts, a phenomenon where neutrophils, being the most abundant leukocyte subtype, are often the primary contributors.^{[17], [18]}Socioeconomic factors also play a role, with lower socioeconomic status correlating with altered leukocyte counts, suggesting broader environmental determinants impacting hematopoietic system regulation.^[18] These external influences highlight how an individual’s surroundings and daily habits can affect the production and mobilization of immune cells.

Geographic and ethnic disparities in neutrophil counts are well-documented, with varying prevalence of neutropenia observed across different populations.^[17]For instance, the phenomenon of benign ethnic neutropenia, characterized by lower neutrophil counts in individuals of African descent, is a recognized example.^[6] This specific ethnic variation is partly explained by the aforementioned DARCgenetic variant, which represents a crucial gene-environment interaction. This genetic adaptation, possibly driven by selective pressures such as malaria, has influenced neutrophil phenotypes in specific populations.^{[3], [14]}

Complex Interactions and Clinical Context

The neutrophil count is also shaped by intricate interactions, including gene-environment dynamics, as well as various comorbidities and therapeutic interventions. TheDARCgene variant, which reduces neutrophil counts in certain populations, simultaneously confers a selective advantage against malaria.^[3] This exemplifies a powerful gene-environment interaction where evolutionary pressures have favored genetic traits that, in turn, influence baseline immune cell levels.

Beyond genetic and environmental interactions, several clinical conditions and medical treatments can substantially impact neutrophil levels. Diseases such as cancer and AIDS are known to cause significant alterations in blood cell counts, frequently leading to neutropenia.^[3]Systemic inflammation, often associated with cardiovascular disease risk factors like elevated blood pressure and adiposity, can result in higher leukocyte counts, with neutrophils being key mediators of these inflammatory processes.^{[1], [18]}Furthermore, medications such as interferon, used in the treatment of chronic hepatitis C, can induce cytopenia, directly affecting neutrophil counts.^[19] while hematopoietic growth factors can be utilized to stimulate blood cell production.^[20]Physiological factors like age and sex also contribute to the observed variations in neutrophil counts within the general population.^[17]

Biological Background

Neutrophil count, a critical component of the white blood cell (WBC) differential, represents the number of neutrophils circulating in the peripheral blood. These highly specialized white blood cells are essential mediators of the innate immune system, playing a fundamental role in defending the body against invading foreign microorganisms and contributing to inflammatory responses . This mobilization process is further fine-tuned by the coordinated action ofG-CSF with specific ELR+CXC chemokines, which is particularly important during acute inflammatory responses.^[21] The chemokine receptors CXCR2 and CXCR4play antagonistic roles in regulating neutrophil trafficking from the bone marrow, with their balanced activity determining the rate of neutrophil egress and retention.^[22]Intracellular signaling cascades initiated by these receptors are essential for proper neutrophil function and numbers. The transcription factorSTAT3acts as a key mediator in these pathways, directly controlling the neutrophil migratory response toCXCR2 ligands.^[23] STAT3 achieves this by activating G-CSF-induced CXCR2 expression and by modulating the downstream signal transduction pathways of CXCR2.^[23]thereby forming a critical feedback loop that ensures appropriate neutrophil levels in circulation.

Cell Cycle, Differentiation, and Protein Turnover Mechanisms

Precise control over hematopoietic progenitor cell proliferation and differentiation is fundamental to regulating neutrophil count.CDK6 (cyclin-dependent kinase 6) functions as a crucial regulator of cell progression in proliferating hematopoietic progenitor cells.^[3] This kinase actively inhibits terminal granulocytic differentiation through its interaction with the transcription factor Runx1.^[3] Genetic variants, such as rs445 located within the first intron of CDK6, have been identified as lead SNPs associated with white blood cell and neutrophil counts, indicating its significant role in modulating neutrophil production.^{[3], [4]}Furthermore, the ubiquitin-proteasome pathway, a core mechanism for regulated protein degradation (catabolism), is implicated in neutrophil count regulation.PSMD3, which encodes a non-ATPase subunit of the 19S regulator of the 26S proteasome, is involved in regulating the cell cycle via this pathway.^[3] Common variations in the PSMD3-CSF3locus are associated with neutrophil count, with research suggesting that the association is primarily driven byPSMD3 expression rather than CSF3.^{[1], [3], [4]}This highlights how precise protein modification and degradation are integral regulatory mechanisms for maintaining neutrophil homeostasis.

Genetic Architecture and Transcriptional Regulation

Genome-wide association studies (GWAS) have revealed multiple genetic loci that significantly influence neutrophil count, demonstrating the polygenic nature of this trait.^{[1], [4]} Beyond the CDK6 and PSMD3-CSF3 loci, common variations in the PLCB4gene have also been associated with neutrophil count.^{[4], [24]}These genetic associations underscore the complex transcriptional and regulatory networks that govern neutrophil production and survival.

A notable example of gene regulation impacting neutrophil count involves a regulatory variant in the Duffy antigen receptor for chemokines gene, which is responsible for the reduced neutrophil counts observed in individuals of African descent, a condition known as benign ethnic neutropenia.^{[1], [14], [19]} Additionally, genes from the GSDML (gasdermin L) and MED (mediator complex subunit) families, along with ORMDL3, have been identified in significant gene clusters associated with total white blood cell and neutrophil counts.^[1] Cis-eQTL effects have shown that genetic variations in these regions correlate with changes in ORMDL3 and GSDMLtranscript expression, suggesting that polymorphism-based regulation of gene expression is a key mechanism influencing neutrophil variation.^[1]

Systems-Level Integration and Disease Relevance

The regulation of neutrophil count is not a simple linear process but rather an outcome of systems-level integration, involving extensive pathway crosstalk and network interactions among diverse signaling, regulatory, and genetic mechanisms. The identified genetic loci, such as those nearPSMD3-CSF3 and CDK6, demonstrate significant interconnectivity across various granulocyte and non-granulocyte cell lineages, pointing to a hierarchical regulation that impacts broader hematopoietic parameters.^[1]This complex interplay results in emergent properties that maintain neutrophil homeostasis under diverse physiological conditions.

Dysregulation within these integrated pathways can lead to significant clinical consequences, including neutropenia. Understanding these mechanisms offers crucial insights into disease-relevant processes, such as the genetic basis of benign ethnic neutropenia or severe congenital neutropenia.^{[5], [6]}Elucidating these pathways also informs the development of therapeutic targets for conditions involving abnormal neutrophil counts, such as cancer-associated neutropenia or strategies for hematopoietic stem cell mobilization.^[3]

Frequently Asked Questions About Neutrophil Count

These questions address the most important and specific aspects of neutrophil count based on current genetic research.

---

1. My doctor says my neutrophils are low. Will my kids inherit this?

It’s possible. Neutrophil count is a moderately heritable trait, meaning genetic factors play a significant role in its variation. If your low count is due to specific genetic predispositions, such as those seen in rare conditions like severe congenital neutropenia, there’s a chance your children could inherit these genetic variants. However, many factors influence neutrophil levels, so it’s not a certainty for all cases.

2. I’m Black and my neutrophils are low. Am I more prone to infections?

Not necessarily. For individuals of African descent, lower neutrophil counts are often a phenomenon called benign ethnic neutropenia (BEN). This is largely due to a common regulatory variant in theDARCgene. Importantly, this genetic predisposition typically doesn’t increase your risk of infection, so your immune system is still functioning effectively.

3. Why do some people rarely get sick, but I catch everything?

Your immune system’s strength, including your neutrophil count, can be influenced by genetics. While variations in genes likeDARC, PSMD3-CSF3, and CDK6can affect neutrophil levels, lifestyle and environmental exposures also play a big role. If your neutrophil count is consistently low (neutropenia), it can make you more susceptible to infections.

4. Does being really stressed out affect my immune cells?

Yes, it can. Stress is one of the factors that can lead to an elevated neutrophil count, a condition known as neutrophilia. While this is often a temporary response to the body being under duress, chronic stress can have broader impacts on your overall health and immune function.

5. Can my neutrophil count tell me about my heart risk?

It can offer some insights. Your total white blood cell count, which is largely driven by your neutrophil count, has been associated with cardiovascular disease risk factors. These include things like high blood pressure, smoking, and adiposity. So, an elevated count might be one indicator for your doctor to consider when assessing your heart health.

6. Does my ethnic background change what’s ‘normal’ for my blood count?

Yes, absolutely. Genetic variations linked to ancestry, such as the DARCgene variant common in people of African descent, can naturally lead to lower neutrophil counts. Recognizing these population-specific differences is crucial for doctors to establish appropriate normal ranges, ensuring you receive equitable and accurate healthcare.

7. Why might a healthy person have a low neutrophil count?

This can happen due to genetic factors, particularly in certain ethnic groups. For example, many people of African descent have naturally lower neutrophil counts, a condition known as benign ethnic neutropenia, which is influenced by a variant in theDARC gene. Despite these lower numbers, their immune system functions normally, and they aren’t at increased risk for infections.

8. I smoke; does that impact my white blood cell count?

Yes, smoking is known to impact your white blood cell count, which is largely made up of neutrophils. Studies have shown an association between smoking and higher white blood cell counts. This is considered a cardiovascular disease risk factor, highlighting another reason to consider quitting for your overall health.

9. My sibling has a strong immune system, but mine is weak. Why?

Individual differences in immune strength, including neutrophil levels, can be influenced by your unique genetic makeup. While you share many genes with your sibling, variations in genes likeDARC, PSMD3-CSF3, or CDK6can lead to different neutrophil counts and immune responses between family members. Environmental factors also play a role.

10. If I’m on chemo, why do I get so many infections?

Chemotherapy is a common cause of neutropenia, which means a lower-than-normal neutrophil count. Since neutrophils are your body’s primary defense against infection, chemotherapy can severely compromise your ability to fight off pathogens, making you much more susceptible to infections while undergoing treatment.

---

This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.

References

[1] Nalls, M. A., D. J. Couper, T. Tanaka, F. J. van Rooij, M. H. Chen, et al. “Multiple loci are associated with white blood cell phenotypes.” PLoS Genetics, vol. 7, no. 6, 2011, p. e1002063.

[2] Metcalf, D. “Hematopoietic cytokines.” Blood, vol. 111, 2008, pp. 485–491.

[3] Reiner, A. P., et al. “Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT).” PLoS Genetics, 2011, PMID: 21738479.

[4] Okada, Y., et al. “Identification of nine novel loci associated with white blood cell subtypes in a Japanese population.” PLoS Genetics, 2011, PMID: 21738478.

[5] Dale, D. C., and D. C. Link. “The many causes of severe congenital neutropenia.” N Engl J Med, vol. 360, 2009, pp. 3–5.

[6] Haddy, T. B., et al. “Benign ethnic neutropenia: what is a normal absolute neutrophil count?”Journal of Laboratory and Clinical Medicine, vol. 133, 1999, pp. 15-22.

[7] Stahl EA et al. “Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci.”Nat Genet, 2010.

[8] Plenge RM et al. “Two independent alleles at 6q23 associated with risk of rheumatoid arthritis.”Nat Genet, 2007.

[9] Loya H et al. “A scalable variational inference approach for increased mixed-model association power.” Nat Genet, 2023.

[10] Cichon S et al. “Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder.” Am J Hum Genet, 2011.

[11] Genetic Association Studies Collaborative. Elucidating Genetic Determinants of Hematological Traits. Human Genomics Research. 2023.

[12] Pilia, G., et al. “Heritability of cardiovascular and personality traits in 6,148 Sardinians.”PLoS Genetics, vol. 2, 2006, e132.

[13] Whitfield, J. B., and N. G. Martin. “Genetic and environmental influences on the size and number of cells in the blood.”Genet Epidemiol, vol. 2, 1985, pp. 133–144.

[14] Reich, D., et al. “Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene.”PLoS Genetics, vol. 5, 2009, e1000360.

[15] Nalls, M. A., et al. “Admixture mapping of white cell count: genetic locus responsible for lower white blood cell count in the Health ABC and Jackson Heart studies.” American Journal of Human Genetics, vol. 82, 2008, pp. 81–87.

[16] Okada, Y., et al. “Common variations in PSMD3-CSF3 and PLCB4 are associated with neutrophil count.”Human Molecular Genetics, vol. 19, 2010, pp. 2079–2085.

[17] Hsieh, M. M., et al. “Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences.” Annals of Internal Medicine, vol. 146, 2007, pp. 486-492.

[18] Nieto, F. J., M. Szklo, A. R. Folsom, R. Rock, and M. Mercuri. “Leukocyte count correlates in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.”Am J Epidemiol, vol. 136, 1992, pp. 525–537.

[19] Thompson, A. J., A. Muir, M. Sulkowski, et al. “Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.”J Hepatol, 2011.

[20] Tillmann, H. L., K. Patel, and J. G. McHutchison. “Role of growth factors and throm-bopoietic agents in the treatment of chronic hepatitis C.”Curr Gastroenterol Rep, vol. 11, 2009, pp. 5–14.

[21] Wengner, A. M., et al. “The coordinated action of G-CSF and ELR+CXC chemokines in neutrophil mobilization during acute inflammation.”Blood, vol. 111, 2008, pp. 42–49.

[22] Eash, K. J., A. M. Greenbaum, P. K. Gopalan, and D. C. Link. “CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow.”Journal of Clinical Investigation, vol. 120, 2010, pp. 2423–31.

[23] Nguyen-Jackson, H., A. D. Panopoulos, H. Zhang, H. S. Li, and S. S. Watowich. “STAT3 controls the neutrophil migratory response to CXCR2 ligands by direct activation of G-CSF-induced CXCR2 expression and via modulation of CXCR2 signal transduction.”Blood, vol. 115, 2010, pp. 3354–63.

[24] Kamatani, Y., et al. “Genome-wide association study of hematological and biochemical traits in a Japanese population.”Nature Genetics, vol. 42, 2010, pp. 210-215.